Insider · CIK 0001701346
John Ballantyne
Files at GCTK (Glucotrack, Inc.). First filing -, latest -.
John Ballantyne files SEC Form 4 as director and 10% owner at GCTK (Glucotrack, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; John Ballantyne has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 9 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Nov 14, 2024 | GCTK Glucotrack, Inc. | JOther Common Stock, par value $0.001 per shareindirect: John A. Ballantyne Rev Trust 08/01/2017 | +132,036 | $31.00 | $4.1M | 183,039 | Mar 31, 2025 |
| Mar 12, 2025 | GCTK Glucotrack, Inc. | XIn-the-money exercise Common Stock, par value $0.001 per shareindirect: John A. Ballantyne Rev Trust 08/01/2017 | +2,560,553 | $0.00 | $0 | 2,743,591 | Mar 31, 2025 |
| Mar 26, 2025 | GCTK Glucotrack, Inc. | AGrant or award Common Stock, par value $0.001 per share | +4,126 | $0.00 | $0 | 4,126 | Mar 31, 2025 |
| Jul 30, 2024 | GCTK Glucotrack, Inc. | POpen-market purchase Warrants to Purchase Common Stockderivativeindirect: John A. Ballantyne Rev Trust 08/01/2017 | +106,667 | - | - | 106,667 | Mar 31, 2025 |
| Jul 30, 2024 | GCTK Glucotrack, Inc. | POpen-market purchase Warrants to Purchase Common Stockderivativeindirect: John A. Ballantyne Rev Trust 08/01/2017 | +76,191 | - | - | 76,191 | Mar 31, 2025 |
| Jul 30, 2024 | GCTK Glucotrack, Inc. | POpen-market purchase Warrants to Purchase Common Stockderivativeindirect: John A. Ballantyne Rev Trust 08/01/2017 | +59,260 | - | - | 59,260 | Mar 31, 2025 |
| Nov 14, 2024 | GCTK Glucotrack, Inc. | AGrant or award Series A Common Warrantderivativeindirect: John A. Ballantyne Rev Trust 08/01/2017 | +132,036 | - | - | 132,036 | Mar 31, 2025 |
| Nov 14, 2024 | GCTK Glucotrack, Inc. | AGrant or award Series B Common Warrantderivativeindirect: John A. Ballantyne Rev Trust 08/01/2017 | +132,036 | - | - | 132,036 | Mar 31, 2025 |
| Mar 12, 2025 | GCTK Glucotrack, Inc. | XIn-the-money exercise Series B Common Warrantderivativeindirect: John A. Ballantyne Rev Trust 08/01/2017 | -132,036 | $0.00 | $0 | 0 | Mar 31, 2025 |
Questions about John Ballantyne
Answered from the filings on this page, as of the latest one.
Is John Ballantyne buying or selling?
John Ballantyne has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did John Ballantyne's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and John Ballantyne has 0.
Where does John Ballantyne file Form 4?
John Ballantyne has filed Form 4 at GCTK (Glucotrack, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.